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Clinical context 
In the preterm infant requiring respiratory support for apnoea, respiratory distress syndrome 
(RDS) or chronic lung disease (CLD), a variety of non-invasive ventilation options are 
available.  Nasal continuous positive airway pressure (CPAP) is commonly used as an 
alternative to endotracheal intubation and more recently, high flow nasal cannula (HFNC) is 
being used to deliver positive end-expiratory pressure (PEEP), oxygen, blended oxygen and 
air.  
Both methods however may have adverse effects despite being moderately easy to apply 
and manage.  The most significant risks related to nasal CPAP are nasal trauma and 
distortion of the nares, and for HFNC, mucosal irritation, obstruction, nosocomial infection 
and possible lung injury from PEEP which is not measured and inconsistent. 
The aim of this Cochrane Review was to compare the safety and efficacy of HFNC with 
other forms of non-invasive respiratory support in preterm infants.   
Inclusion criteria 
Studies 
Randomised and quasi-randomised studies (including crossover trials). 
Participants 
Preterm infants (<37 weeks gestational age) receiving respiratory support after birth with or 
without a prior period of intermittent positive pressure ventilation (IPPV).   
Intervention 
HFNC oxygen - defined as the delivery of oxygen or blended oxygen and air via a nasal 
cannula at flow rates of >1 litre per minute (lpm). 
Alternative interventions included: head box oxygen, low flow (≤1 lpm) nasal cannulae, nasal 
CPAP, non-invasive IPPV, HFNC using an alternative technique (e.g. humidified versus non-
humidified, or different models of HFNC). 
Outcomes 
The primary outcomes included death (prior to discharge), CLD and need for reintubation. 
Secondary outcomes included duration of respiratory support, length of stay, air leak 
syndromes, nasal trauma, nosocomial sepsis, gastrointestinal complications, growth, days to 
full feeds, retinopathy of prematurity and neurodevelopmental outcomes. 
Results  
Four small trials including 177 infants were identified for inclusion in the review.  One study 
is awaiting assessment and there were a further five studies identified that are currently in 
progress. 
Each study differed in the intervention compared, the flow rate and indication for use:  
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• HFNC compared to nasal CPAP in preterm infants for treatment or prophylaxis of 
RDS and post extubation;  
• Humidified HFNC to non-humidified HFNC in preterm infants post extubation 
• and two types of humidified HFNC equipment used in preterm infants post 
extubation.   
Risk of bias: Risk of selection bias was generally low, performance and detection bias 
generally high. 
One trial found no difference in the rates of failure in infants treated with HFNC (n=4/33) and 
nasal CPAP (n=4/34) when used as the primary respiratory support after birth (Relative Risk, 
RR, 1.03; 95% CI 0.28 to 3.78). 
One trial found a significantly higher risk of reintubation in those infants treated with HFNC 
(n=12/20) compared with nasal CPAP (n=3/20) when used following extubation (RR 4.0; 
95% CI 1.33 to 12.05).  
There was no significant difference in the need for reintubation in the one trial comparing 
humidified (n=0/15) and non-humidified (n=2/15) HFNC (RR 0.17; 95% CI 0.01 to 3.34) and 
no difference found in the one trial comparing two different models of equipment used to 
deliver humidified HFNC (RR 1.35, 95% CI 0.31 to 5.90).  
For all studies where secondary outcomes were measured these did not differ between 
groups. 
Authors’ conclusions 
Implications for practice 
Currently there is insufficient evidence to determine the safety and efficacy of HFNC for 
respiratory support in preterm infants.  HFNC may be associated with a higher rate of 
reintubation when used following extubation than nasal CPAP. 
Implications for research 
Further randomised controlled trials in preterm infants comparing HFNC with nasal CPAP 
and other means of respiratory support, or of support following extubation are required.  
Trials need to be sufficiently powered to detect differences in clinically important outcomes 
including death, CLD, need for mechanical ventilation and duration of respiratory support.  If 
HFNC is shown to be effective, further research should aim to establish in which subgroups 
of infants and which type of delivery (eg nasal cannula size, flow rates, temperature and 
humidity settings).  
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